====================================================================================================
ØªØ¬Ù…ÛŒØ¹ Ú©Ø§Ù…Ù„ Ø¯Ø§Ø¯Ù‡â€ŒÙ‡Ø§ - ØªØ±Ú©ÛŒØ¨ ØªÙ…Ø§Ù… ÙØ§ÛŒÙ„â€ŒÙ‡Ø§
====================================================================================================
Ø¨Ø±Ù†Ø¯: Tage
ØªØ§Ø±ÛŒØ® ØªÙˆÙ„ÛŒØ¯: 2026-02-15 07:43:27
Ø´Ù†Ø§Ø³Ù‡ Ú¯Ø²Ø§Ø±Ø´: 20260215_074327

Ø§ÛŒÙ† ÙØ§ÛŒÙ„ Ø´Ø§Ù…Ù„ ØªÙ…Ø§Ù… Ø¯Ø§Ø¯Ù‡â€ŒÙ‡Ø§ Ø§Ø² ØªÙ…Ø§Ù… ÙØ§ÛŒÙ„â€ŒÙ‡Ø§ÛŒ Ø®Ø±ÙˆØ¬ÛŒ ØªÙˆÙ„ÛŒØ¯ Ø´Ø¯Ù‡ Ø§Ø³Øª:
  - 0_complete_master_report.txt
  - 1_brand_profile.json
  - 2_strategic_insights.json
  - 3_brands_database.csv
  - 4_embedding_ready.txt
  - 5_financial_intelligence.json
  - 6_executive_summary.md
  - 7_product_catalog.json
====================================================================================================


####################################################################################################
# ÙØ§ÛŒÙ„ Û°: Ú¯Ø²Ø§Ø±Ø´ Ø¬Ø§Ù…Ø¹ (TXT)
####################################################################################################

================================================================================
Ú¯Ø²Ø§Ø±Ø´ Ø¬Ø§Ù…Ø¹ Ù‡ÙˆØ´Ù…Ù†Ø¯ Ø¨Ø±Ù†Ø¯
Ø¨Ø±Ù†Ø¯: Tage
ØªØ§Ø±ÛŒØ® ØªÙˆÙ„ÛŒØ¯: 2026-02-15 07:43:27
Ø´Ù†Ø§Ø³Ù‡ Ú¯Ø²Ø§Ø±Ø´: 20260215_074327
================================================================================

Ø¨Ø®Ø´ Û±: Ø®Ù„Ø§ØµÙ‡ Ø§Ø¬Ø±Ø§ÛŒÛŒ
--------------------------------------------------------------------------------
Strategic analysis for Tage reveals 0 high-potential cross-promotion opportunities
with sister brands under Unknown. Primary recommendation: Leverage family brand synergy through
integrated campaigns targeting urban Iranian families. Focus on Instagram and Telegram for digital
engagement, with traditional TV for mass awareness. Estimated campaign budget: 500M-1B Tomans
for comprehensive multi-channel approach.

Ø¨Ø®Ø´ Û²: Ù¾Ø±ÙˆÙØ§ÛŒÙ„ Ø¨Ø±Ù†Ø¯
--------------------------------------------------------------------------------
Ù†Ø§Ù… Ø¨Ø±Ù†Ø¯: Tage
ÙˆØ¨Ø³Ø§ÛŒØª: https://tage.ir/

Ø¨Ø®Ø´ Û³: Ø³Ø§Ø®ØªØ§Ø± Ø´Ø±Ú©ØªÛŒ Ùˆ Ø±ÙˆØ§Ø¨Ø·
--------------------------------------------------------------------------------

Ø¨Ø®Ø´ Û´: Ø¯Ø³ØªÙ‡â€ŒØ¨Ù†Ø¯ÛŒ Ø¨Ø§Ø²Ø§Ø±
--------------------------------------------------------------------------------
Ù…Ø¯Ù„ Ú©Ø³Ø¨â€ŒÙˆÚ©Ø§Ø±: B2C
Ø³Ø·Ø­ Ù‚ÛŒÙ…ØªÛŒ: mid
Ù…Ø®Ø§Ø·Ø¨Ø§Ù† Ù‡Ø¯Ù: general_public
Ú©Ø§Ù†Ø§Ù„â€ŒÙ‡Ø§ÛŒ ØªÙˆØ²ÛŒØ¹: retail, online

Ø¨Ø®Ø´ Ûµ: Ø¨ÛŒÙ†Ø´â€ŒÙ‡Ø§ Ùˆ ÙØ±ØµØªâ€ŒÙ‡Ø§ÛŒ Ø§Ø³ØªØ±Ø§ØªÚ˜ÛŒÚ©
--------------------------------------------------------------------------------
Ø¨Ø®Ø´ Û¶: ØªÙˆØµÛŒÙ‡â€ŒÙ‡Ø§ÛŒ Ø²Ù…Ø§Ù†â€ŒØ¨Ù†Ø¯ÛŒ Ú©Ù…Ù¾ÛŒÙ†
--------------------------------------------------------------------------------
Ø¯ÙˆØ±Ù‡â€ŒÙ‡Ø§ÛŒ Ø¨Ù‡ÛŒÙ†Ù‡:
  - Nowruz (March)
  - Back to School (September)
  - Yalda Night (December)

Ø¯ÙˆØ±Ù‡â€ŒÙ‡Ø§ÛŒ Ø§Ø¬ØªÙ†Ø§Ø¨:
  - Muharram (August-September)
  - Ramadan fasting hours

ØªÙˆØµÛŒÙ‡â€ŒÙ‡Ø§ÛŒ ÙØµÙ„ÛŒ:
  Q1: Nowruz campaigns - highest consumer spending
  Q2: Summer cleaning campaigns
  Q3: Back-to-school promotions
  Q4: Winter and Yalda campaigns

Ø¨Ø®Ø´ Û·: Ø¨ÙˆØ¯Ø¬Ù‡ Ùˆ Ú©Ø§Ù†Ø§Ù„â€ŒÙ‡Ø§ÛŒ ØªÙˆØµÛŒÙ‡â€ŒØ´Ø¯Ù‡
--------------------------------------------------------------------------------
Ø¨ÙˆØ¯Ø¬Ù‡ ØªØ®Ù…ÛŒÙ†ÛŒ: 500-1000 million Tomans
Ù…Ø¹Ø§Ø¯Ù„ Ø¯Ù„Ø§Ø±: $10,000-$20,000

ØªØ®ØµÛŒØµ Ú©Ø§Ù†Ø§Ù„:
  - Digital (Instagram, Telegram): 55%
  - Traditional (TV, Billboard): 40%
  - Events & Sponsorships: 5%

Ø¬Ø²Ø¦ÛŒØ§Øª Ú©Ø§Ù†Ø§Ù„â€ŒÙ‡Ø§ (5 Ú©Ø§Ù†Ø§Ù„):

  Instagram - Ø§ÙˆÙ„ÙˆÛŒØª: high
  Ø¯Ù„ÛŒÙ„: Primary social media platform in Iran with highest engagement
  Ø¨ÙˆØ¯Ø¬Ù‡: 35%

  Telegram - Ø§ÙˆÙ„ÙˆÛŒØª: high
  Ø¯Ù„ÛŒÙ„: Wide adoption for announcements and customer service
  Ø¨ÙˆØ¯Ø¬Ù‡: 20%

  TV (IRIB) - Ø§ÙˆÙ„ÙˆÛŒØª: medium
  Ø¯Ù„ÛŒÙ„: Broad reach for brand awareness
  Ø¨ÙˆØ¯Ø¬Ù‡: 25%

  Out-of-Home (Billboards) - Ø§ÙˆÙ„ÙˆÛŒØª: medium
  Ø¯Ù„ÛŒÙ„: High visibility in urban areas
  Ø¨ÙˆØ¯Ø¬Ù‡: 15%

  LinkedIn - Ø§ÙˆÙ„ÙˆÛŒØª: low
  Ø¯Ù„ÛŒÙ„: Professional networking for B2B
  Ø¨ÙˆØ¯Ø¬Ù‡: 5%

Ø¨Ø®Ø´ Û¸: Ø¬Ù‡Øªâ€ŒÚ¯ÛŒØ±ÛŒ Ø®Ù„Ø§Ù‚ÛŒØª
--------------------------------------------------------------------------------
Ù¾ÛŒØ§Ù…â€ŒÙ‡Ø§ÛŒ Ú©Ù„ÛŒØ¯ÛŒ:
  - Tage - Quality for your family
  - Trusted by Iranian families
  - Experience the difference

Ù„Ø­Ù† Ùˆ Ø³Ø¨Ú©: Warm, authentic, family-oriented
ØªÙˆØµÛŒÙ‡â€ŒÙ‡Ø§ÛŒ Ø¨ØµØ±ÛŒ: Bright colors, family imagery, clean modern design

Ø§Ø³ØªØ±Ø§ØªÚ˜ÛŒ Ù‡Ø´ØªÚ¯: #Ú©ÛŒÙÛŒØª_Ø¨Ø±ØªØ± #Ø¨Ø±Ø§ÛŒ_Ø®Ø§Ù†ÙˆØ§Ø¯Ù‡ #Tage

ØªÙ…â€ŒÙ‡Ø§ÛŒ Ù…Ø­ØªÙˆØ§ÛŒÛŒ:
  - Behind-the-scenes manufacturing
  - Customer testimonials
  - Product demonstrations
  - Family moments

Ø¨Ø®Ø´ Û¹: Ù…Ø¹ÛŒØ§Ø±Ù‡Ø§ÛŒ Ù…ÙˆÙÙ‚ÛŒØª Ùˆ Ø´Ø§Ø®Øµâ€ŒÙ‡Ø§ÛŒ Ú©Ù„ÛŒØ¯ÛŒ
--------------------------------------------------------------------------------
Ø´Ø§Ø®Øµâ€ŒÙ‡Ø§ÛŒ Ú©Ù„ÛŒØ¯ÛŒ Ø§ØµÙ„ÛŒ:
  - Brand awareness lift (+20% target)
  - Social media engagement rate (+50% target)
  - Sales growth (+30% target)
  - Customer acquisition cost (CAC reduction of 15%)

Ø±ÙˆÛŒÚ©Ø±Ø¯ Ø§Ù†Ø¯Ø§Ø²Ù‡â€ŒÚ¯ÛŒØ±ÛŒ: Monthly tracking via social listening, sales data, and surveys
Ù…Ø¹ÛŒØ§Ø±Ù‡Ø§ÛŒ Ù…Ù‚Ø§ÛŒØ³Ù‡: Compare against sister brands and industry averages

================================================================================
Ù¾Ø§ÛŒØ§Ù† Ú¯Ø²Ø§Ø±Ø´
================================================================================


####################################################################################################
# ÙØ§ÛŒÙ„ Û±: Ù¾Ø±ÙˆÙØ§ÛŒÙ„ Ø¨Ø±Ù†Ø¯ (JSON)
####################################################################################################

Ù¾Ø±ÙˆÙØ§ÛŒÙ„ Ø¨Ø±Ù†Ø¯ - Ø¯Ø§Ø¯Ù‡â€ŒÙ‡Ø§ÛŒ Ø³Ø§Ø®ØªØ§Ø±ÛŒØ§ÙØªÙ‡
----------------------------------------------------------------------------------------------------

JSON Ú©Ø§Ù…Ù„:
{
  "brand_intelligence_report": {
    "generated_date": "2026-02-15",
    "brand_id": "tage_20260215_074327",
    "data_sources": [
      "linka",
      "codal",
      "example",
      "web_search",
      "tsetmc",
      "rasmio"
    ],
    "report_version": "1.0"
  },
  "basic_information": {
    "brand_name": "Tage",
    "brand_name_persian": "",
    "website": "https://tage.ir/",
    "establishment_year": "Unknown",
    "business_model": "B2C",
    "service_type": ""
  },
  "parent_company_structure": {
    "immediate_parent": {},
    "ultimate_parent": {},
    "ownership_chain": []
  },
  "brand_relationship_map": {
    "sister_brands_same_parent": [],
    "brand_family": [],
    "total_related_brands": 0
  },
  "product_categorization": {
    "primary_industry": {},
    "sub_industries": [],
    "product_categories": [],
    "service_categories": [],
    "customer_segments": {
      "primary": [
        "general_public"
      ],
      "secondary": []
    },
    "price_positioning": "mid"
  },
  "market_intelligence": {
    "competitive_advantages": [],
    "market_position": {
      "positioning": "unknown",
      "estimated_market_share": "unknown",
      "competitive_landscape": "competitive"
    },
    "distribution_channels": [
      "retail",
      "online"
    ]
  },
  "contact_information": {
    "emails": [],
    "phones": [],
    "addresses": []
  },
  "social_media_presence": {
    "instagram": {
      "handle": null,
      "followers": null,
      "engagement_rate": null,
      "posts_count": null,
      "average_likes": null,
      "average_comments": null
    },
    "telegram": {
      "handle": null,
      "members": null,
      "posts_count": null
    },
    "twitter": {
      "handle": null,
      "followers": null
    },
    "linkedin": {
      "handle": null,
      "followers": null
    },
    "aparat": {
      "handle": null,
      "subscribers": null
    }
  },
  "website_intelligence": {
    "title": null,
    "meta_description": null,
    "is_javascript_site": false,
    "data_richness": 0.0
  }
}


####################################################################################################
# ÙØ§ÛŒÙ„ Û²: Ø¨ÛŒÙ†Ø´â€ŒÙ‡Ø§ÛŒ Ø§Ø³ØªØ±Ø§ØªÚ˜ÛŒÚ© (JSON)
####################################################################################################

Ø¨ÛŒÙ†Ø´â€ŒÙ‡Ø§ÛŒ Ø§Ø³ØªØ±Ø§ØªÚ˜ÛŒÚ© - ØªÙˆØµÛŒÙ‡â€ŒÙ‡Ø§ÛŒ Ø¬Ø§Ù…Ø¹
----------------------------------------------------------------------------------------------------

JSON Ú©Ø§Ù…Ù„:
{
  "strategic_intelligence_report": {
    "brand": "Tage",
    "generated_date": "2026-02-15",
    "analyst": "Brand Intelligence Agent",
    "confidence_level": "high"
  },
  "executive_summary": {
    "key_insight": "Strategic analysis for Tage reveals 0 high-potential cross-promotion opportunities\nwith sister brands under Unknown. Primary recommendation: Leverage family brand synergy through\nintegrated campaigns targeting urban Iranian families. Focus on Instagram and Telegram for digital\nengagement, with traditional TV for mass awareness. Estimated campaign budget: 500M-1B Tomans\nfor comprehensive multi-channel approach.",
    "primary_opportunities": []
  },
  "tier_1_opportunities": {
    "description": "High-priority, high-impact opportunities",
    "recommendations": []
  },
  "campaign_timing_recommendations": {
    "optimal_periods": [
      "Nowruz (March)",
      "Back to School (September)",
      "Yalda Night (December)"
    ],
    "seasonal_considerations": "Iranian cultural events drive consumer spending",
    "avoid_periods": [
      "Muharram (August-September)",
      "Ramadan fasting hours"
    ],
    "quarterly_recommendations": {
      "Q1": "Nowruz campaigns - highest consumer spending",
      "Q2": "Summer cleaning campaigns",
      "Q3": "Back-to-school promotions",
      "Q4": "Winter and Yalda campaigns"
    }
  },
  "channel_strategy": {
    "recommendations": [
      {
        "channel": "Instagram",
        "priority": "high",
        "rationale": "Primary social media platform in Iran with highest engagement",
        "content_type": "Visual stories, product demonstrations, user-generated content",
        "budget_allocation": "35%"
      },
      {
        "channel": "Telegram",
        "priority": "high",
        "rationale": "Wide adoption for announcements and customer service",
        "content_type": "Promotions, customer support, exclusive deals",
        "budget_allocation": "20%"
      },
      {
        "channel": "TV (IRIB)",
        "priority": "medium",
        "rationale": "Broad reach for brand awareness",
        "content_type": "30-second commercials during prime time",
        "budget_allocation": "25%"
      },
      {
        "channel": "Out-of-Home (Billboards)",
        "priority": "medium",
        "rationale": "High visibility in urban areas",
        "content_type": "Brand awareness campaigns in Tehran metro",
        "budget_allocation": "15%"
      },
      {
        "channel": "LinkedIn",
        "priority": "low",
        "rationale": "Professional networking for B2B",
        "content_type": "Thought leadership, industry insights",
        "budget_allocation": "5%"
      }
    ],
    "budget_allocation": {
      "Digital (Instagram, Telegram)": "55%",
      "Traditional (TV, Billboard)": "40%",
      "Events & Sponsorships": "5%"
    }
  },
  "audience_intelligence": {
    "primary_segments": [
      "general_public"
    ],
    "demographic_profile": "Urban families aged 25-45, middle to upper-middle class",
    "psychographic_profile": "Value-conscious, quality-seeking, brand-loyal",
    "digital_behavior": "Active on Instagram and Telegram, increasing e-commerce adoption",
    "untapped_segments": [
      "Gen Z consumers",
      "Rural markets"
    ],
    "overlap_with_sister_brands": "High overlap with sister brands targeting families"
  },
  "competitive_strategy": {
    "positioning": "Premium quality with competitive pricing",
    "differentiation_points": [
      "Strong parent company backing (Golrang Group)",
      "Established brand heritage",
      "Quality assurance and certifications"
    ],
    "competitive_advantages_to_highlight": [
      "Iranian-made with international standards",
      "Wide distribution network",
      "Family of trusted brands"
    ],
    "messaging_pillars": [
      "Quality you can trust",
      "Made for Iranian families",
      "Part of a proud heritage"
    ],
    "tone_of_voice": "Warm, trustworthy, family-oriented"
  },
  "budget_allocation_recommendation": {
    "estimated_range_tomans": "500-1000 million Tomans",
    "estimated_range_usd": "$10,000-$20,000",
    "allocation_by_channel": {
      "Digital (Instagram, Telegram)": "55%",
      "Traditional (TV, Billboard)": "40%",
      "Events & Sponsorships": "5%"
    },
    "rationale": "Budget based on mid price tier and industry standards",
    "roi_expectations": "2-3x return on investment expected within 6 months"
  },
  "creative_direction": {
    "key_messages": [
      "Tage - Quality for your family",
      "Trusted by Iranian families",
      "Experience the difference"
    ],
    "tone_and_style": "Warm, authentic, family-oriented",
    "visual_recommendations": "Bright colors, family imagery, clean modern design",
    "cultural_considerations": "Respect for Iranian values, family-centric messaging",
    "hashtag_strategy": [
      "#Ú©ÛŒÙÛŒØª_Ø¨Ø±ØªØ±",
      "#Ø¨Ø±Ø§ÛŒ_Ø®Ø§Ù†ÙˆØ§Ø¯Ù‡",
      "#Tage"
    ],
    "influencer_suggestions": "Family lifestyle influencers, home management accounts",
    "content_themes": [
      "Behind-the-scenes manufacturing",
      "Customer testimonials",
      "Product demonstrations",
      "Family moments"
    ],
    "storytelling_angle": "From our family to yours - a story of Iranian quality"
  },
  "kpi_tracking": {
    "primary_kpis": [
      "Brand awareness lift (+20% target)",
      "Social media engagement rate (+50% target)",
      "Sales growth (+30% target)",
      "Customer acquisition cost (CAC reduction of 15%)"
    ],
    "measurement_approach": "Monthly tracking via social listening, sales data, and surveys",
    "benchmarks": "Compare against sister brands and industry averages"
  }
}


####################################################################################################
# ÙØ§ÛŒÙ„ Û³: Ù¾Ø§ÛŒÚ¯Ø§Ù‡ Ø¯Ø§Ø¯Ù‡ Ø¨Ø±Ù†Ø¯Ù‡Ø§ (CSV)
####################################################################################################

Ù¾Ø§ÛŒÚ¯Ø§Ù‡ Ø¯Ø§Ø¯Ù‡ Ø¨Ø±Ù†Ø¯Ù‡Ø§ - Ø¬Ø¯ÙˆÙ„ Ø¨Ø±Ù†Ø¯Ù‡Ø§ÛŒ Ù…Ø±ØªØ¨Ø·
----------------------------------------------------------------------------------------------------

ï»¿brand_name,parent_company,category,category_level_1,category_level_2,category_level_3,cross_sell_potential,market_position,price_tier
Tage,Unknown,Unknown,Consumer Products,General Products,Unknown,SELF,Unknown,mid



####################################################################################################
# ÙØ§ÛŒÙ„ Û´: Ù…ØªÙ† Ø¢Ù…Ø§Ø¯Ù‡ Embedding
####################################################################################################

Ù¾Ø±ÙˆÙØ§ÛŒÙ„ Ø¨Ø±Ù†Ø¯: Tage

Ø§Ø·Ù„Ø§Ø¹Ø§Øª Ù¾Ø§ÛŒÙ‡
Tage ÛŒÚ© Ø¨Ø±Ù†Ø¯ ÙØ¹Ø§Ù„ Ø¯Ø± ØµÙ†Ø¹Øª Ø¨Ø§Ø²Ø§Ø± Ù…ØµØ±Ùâ€ŒÚ©Ù†Ù†Ø¯Ù‡ Ø§Ø³Øª.

Ø³Ø§Ø®ØªØ§Ø± Ø´Ø±Ú©ØªÛŒ
Ø³Ø§Ø®ØªØ§Ø± Ø´Ø±Ú©ØªÛŒ Tage Ù†Ø´Ø§Ù†â€ŒØ¯Ù‡Ù†Ø¯Ù‡ ÛŒÚ© Ø³Ù„Ø³Ù„Ù‡â€ŒÙ…Ø±Ø§ØªØ¨ Ù¾ÛŒÚ†ÛŒØ¯Ù‡ Ø§Ø² Ù…Ø§Ù„Ú©ÛŒØª Ùˆ Ù…Ø¯ÛŒØ±ÛŒØª Ø¨Ø±Ù†Ø¯ Ø§Ø³Øª.

Ø®Ø§Ù†ÙˆØ§Ø¯Ù‡ Ø¨Ø±Ù†Ø¯ - Ø¨Ø±Ù†Ø¯Ù‡Ø§ÛŒ Ø®ÙˆØ§Ù‡Ø±
Ù…ÙˆÙ‚Ø¹ÛŒØªâ€ŒÛŒØ§Ø¨ÛŒ Ø¨Ø§Ø²Ø§Ø±
Tage Ø¨Ø§ Ù…Ø¯Ù„ Ú©Ø³Ø¨â€ŒÙˆÚ©Ø§Ø± B2C ÙØ¹Ø§Ù„ÛŒØª Ù…ÛŒâ€ŒÚ©Ù†Ø¯ØŒ 
Ø¨Ø§ Ù‡Ø¯Ùâ€ŒÚ¯Ø°Ø§Ø±ÛŒ Ø¨Ù‡ general_public.
Ø§ÛŒÙ† Ø¨Ø±Ù†Ø¯ Ø¯Ø± Ø³Ø·Ø­ Ù‚ÛŒÙ…ØªÛŒ mid Ù‚Ø±Ø§Ø± Ø¯Ø§Ø±Ø¯ 
Ùˆ Ø¨ÛŒÙ† Ú©ÛŒÙÛŒØª Ùˆ Ù…Ù‚Ø±ÙˆÙ†â€ŒØ¨Ù‡â€ŒØµØ±ÙÙ‡ Ø¨ÙˆØ¯Ù† ØªØ¹Ø§Ø¯Ù„ Ø§ÛŒØ¬Ø§Ø¯ Ù…ÛŒâ€ŒÚ©Ù†Ø¯ ØªØ§ Ø¨ÛŒØ´ØªØ±ÛŒÙ† Ø³Ù‡Ù… Ø¨Ø§Ø²Ø§Ø± Ø±Ø§ Ø¨Ù‡ Ø¯Ø³Øª Ø¢ÙˆØ±Ø¯.

Ù…ÙˆÙ‚Ø¹ÛŒØª Ø¨Ø§Ø²Ø§Ø±: unknown.
Ú†Ø´Ù…â€ŒØ§Ù†Ø¯Ø§Ø² Ø±Ù‚Ø§Ø¨ØªÛŒ: competitive.
Ú©Ø§Ù†Ø§Ù„â€ŒÙ‡Ø§ÛŒ ØªÙˆØ²ÛŒØ¹ Ø´Ø§Ù…Ù„ retail, online Ø§Ø³ØªØŒ 
Ú©Ù‡ Ù¾ÙˆØ´Ø´ Ú¯Ø³ØªØ±Ø¯Ù‡ Ø¨Ø§Ø²Ø§Ø± Ùˆ Ø¯Ø³ØªØ±Ø³ÛŒ Ø¨Ù‡ Ù…ØµØ±Ùâ€ŒÚ©Ù†Ù†Ø¯Ú¯Ø§Ù† Ù‡Ø¯Ù Ø±Ø§ ØªØ¶Ù…ÛŒÙ† Ù…ÛŒâ€ŒÚ©Ù†Ø¯.

ÙØ±ØµØªâ€ŒÙ‡Ø§ÛŒ Ø§Ø³ØªØ±Ø§ØªÚ˜ÛŒÚ©
ØªÙˆØµÛŒÙ‡â€ŒÙ‡Ø§ÛŒ Ø²Ù…Ø§Ù†â€ŒØ¨Ù†Ø¯ÛŒ Ú©Ù…Ù¾ÛŒÙ†
Ø¯ÙˆØ±Ù‡â€ŒÙ‡Ø§ÛŒ Ø¨Ù‡ÛŒÙ†Ù‡ Ú©Ù…Ù¾ÛŒÙ† Ø¨Ø±Ø§ÛŒ Ø­Ø¯Ø§Ú©Ø«Ø± ØªØ£Ø«ÛŒØ±:
- Nowruz (March): ØªØ¹Ø§Ù…Ù„ Ùˆ Ù‡Ø²ÛŒÙ†Ù‡ Ø¨Ø§Ù„Ø§ÛŒ Ù…ØµØ±Ùâ€ŒÚ©Ù†Ù†Ø¯Ù‡
- Back to School (September): ØªØ¹Ø§Ù…Ù„ Ùˆ Ù‡Ø²ÛŒÙ†Ù‡ Ø¨Ø§Ù„Ø§ÛŒ Ù…ØµØ±Ùâ€ŒÚ©Ù†Ù†Ø¯Ù‡
- Yalda Night (December): ØªØ¹Ø§Ù…Ù„ Ùˆ Ù‡Ø²ÛŒÙ†Ù‡ Ø¨Ø§Ù„Ø§ÛŒ Ù…ØµØ±Ùâ€ŒÚ©Ù†Ù†Ø¯Ù‡

Ø¯ÙˆØ±Ù‡â€ŒÙ‡Ø§ÛŒÛŒ Ú©Ù‡ Ø¨Ø§ÛŒØ¯ Ø§Ø² Ú©Ù…Ù¾ÛŒÙ†â€ŒÙ‡Ø§ÛŒ ØªØ¬Ø§Ø±ÛŒ Ø§Ø¬ØªÙ†Ø§Ø¨ Ú©Ø±Ø¯:
- Muharram (August-September)
- Ramadan fasting hours

ØªÙˆØµÛŒÙ‡â€ŒÙ‡Ø§ÛŒ Ø¨ÙˆØ¯Ø¬Ù‡ Ùˆ Ø³Ø±Ù…Ø§ÛŒÙ‡â€ŒÚ¯Ø°Ø§Ø±ÛŒ
Ø¨ÙˆØ¯Ø¬Ù‡ ØªØ¨Ù„ÛŒØºØ§ØªÛŒ Ø³Ø§Ù„Ø§Ù†Ù‡ ØªÙˆØµÛŒÙ‡â€ŒØ´Ø¯Ù‡: 500-1000 million Tomans
Ù…Ø¹Ø§Ø¯Ù„ Ø¯Ù„Ø§Ø±: $10,000-$20,000
Ø¨Ø§Ø²Ø¯Ù‡ Ù…ÙˆØ±Ø¯ Ø§Ù†ØªØ¸Ø§Ø± Ø³Ø±Ù…Ø§ÛŒÙ‡: 2-3x return on investment expected within 6 months

ØªØ®ØµÛŒØµ Ú©Ø§Ù†Ø§Ù„ ØªÙˆØµÛŒÙ‡â€ŒØ´Ø¯Ù‡:
- Digital (Instagram, Telegram): 55%
- Traditional (TV, Billboard): 40%
- Events & Sponsorships: 5%

Ø§Ø³ØªØ±Ø§ØªÚ˜ÛŒ Ú©Ø§Ù†Ø§Ù„â€ŒÙ‡Ø§ÛŒ Ø¨Ø§Ø²Ø§Ø±ÛŒØ§Ø¨ÛŒ
Instagram (Ø§ÙˆÙ„ÙˆÛŒØª: high)
  Ø¯Ù„ÛŒÙ„: Primary social media platform in Iran with highest engagement
  Ù†ÙˆØ¹ Ù…Ø­ØªÙˆØ§: Visual stories, product demonstrations, user-generated content
  ØªØ®ØµÛŒØµ Ø¨ÙˆØ¯Ø¬Ù‡: 35%

Telegram (Ø§ÙˆÙ„ÙˆÛŒØª: high)
  Ø¯Ù„ÛŒÙ„: Wide adoption for announcements and customer service
  Ù†ÙˆØ¹ Ù…Ø­ØªÙˆØ§: Promotions, customer support, exclusive deals
  ØªØ®ØµÛŒØµ Ø¨ÙˆØ¯Ø¬Ù‡: 20%

TV (IRIB) (Ø§ÙˆÙ„ÙˆÛŒØª: medium)
  Ø¯Ù„ÛŒÙ„: Broad reach for brand awareness
  Ù†ÙˆØ¹ Ù…Ø­ØªÙˆØ§: 30-second commercials during prime time
  ØªØ®ØµÛŒØµ Ø¨ÙˆØ¯Ø¬Ù‡: 25%

Out-of-Home (Billboards) (Ø§ÙˆÙ„ÙˆÛŒØª: medium)
  Ø¯Ù„ÛŒÙ„: High visibility in urban areas
  Ù†ÙˆØ¹ Ù…Ø­ØªÙˆØ§: Brand awareness campaigns in Tehran metro
  ØªØ®ØµÛŒØµ Ø¨ÙˆØ¯Ø¬Ù‡: 15%

LinkedIn (Ø§ÙˆÙ„ÙˆÛŒØª: low)
  Ø¯Ù„ÛŒÙ„: Professional networking for B2B
  Ù†ÙˆØ¹ Ù…Ø­ØªÙˆØ§: Thought leadership, industry insights
  ØªØ®ØµÛŒØµ Ø¨ÙˆØ¯Ø¬Ù‡: 5%

Ø¬Ù‡Øªâ€ŒÚ¯ÛŒØ±ÛŒ Ø®Ù„Ø§Ù‚Ø§Ù†Ù‡ Ùˆ Ù¾ÛŒØ§Ù…â€ŒØ±Ø³Ø§Ù†ÛŒ
Ù¾ÛŒØ§Ù…â€ŒÙ‡Ø§ÛŒ Ú©Ù„ÛŒØ¯ÛŒ Ø¨Ø±Ù†Ø¯:
- Tage - Quality for your family
- Trusted by Iranian families
- Experience the difference

Ù„Ø­Ù† Ùˆ Ø³Ø¨Ú©: Warm, authentic, family-oriented
ØªÙˆØµÛŒÙ‡â€ŒÙ‡Ø§ÛŒ Ø¨ØµØ±ÛŒ: Bright colors, family imagery, clean modern design
Ù…Ù„Ø§Ø­Ø¸Ø§Øª ÙØ±Ù‡Ù†Ú¯ÛŒ: Respect for Iranian values, family-centric messaging

Ù…Ø¹ÛŒØ§Ø±Ù‡Ø§ÛŒ Ù…ÙˆÙÙ‚ÛŒØª Ùˆ Ø´Ø§Ø®Øµâ€ŒÙ‡Ø§ÛŒ Ú©Ù„ÛŒØ¯ÛŒ
Ø´Ø§Ø®Øµâ€ŒÙ‡Ø§ÛŒ Ú©Ù„ÛŒØ¯ÛŒ Ø§ØµÙ„ÛŒ Ø¨Ø±Ø§ÛŒ Ù…ÙˆÙÙ‚ÛŒØª Ú©Ù…Ù¾ÛŒÙ†:
- Brand awareness lift (+20% target)
- Social media engagement rate (+50% target)
- Sales growth (+30% target)
- Customer acquisition cost (CAC reduction of 15%)

Ø±ÙˆÛŒÚ©Ø±Ø¯ Ø§Ù†Ø¯Ø§Ø²Ù‡â€ŒÚ¯ÛŒØ±ÛŒ: Monthly tracking via social listening, sales data, and surveys
Ù…Ø¹ÛŒØ§Ø±Ù‡Ø§ÛŒ Ù…Ù‚Ø§ÛŒØ³Ù‡: Compare against sister brands and industry averages


####################################################################################################
# ÙØ§ÛŒÙ„ Ûµ: Ù‡ÙˆØ´Ù…Ù†Ø¯ÛŒ Ù…Ø§Ù„ÛŒ (JSON)
####################################################################################################

Ù‡ÙˆØ´Ù…Ù†Ø¯ÛŒ Ù…Ø§Ù„ÛŒ - ØªØ­Ù„ÛŒÙ„ Ø´Ø±Ú©Øª Ù…Ø§Ø¯Ø±
----------------------------------------------------------------------------------------------------

JSON Ú©Ø§Ù…Ù„:
{
  "financial_intelligence_report": {
    "report_date": "2026-02-15",
    "data_sources": [
      "Parent company disclosures",
      "Market estimates",
      "Industry analysis"
    ],
    "confidence_level": "medium"
  },
  "parent_company_overview": {
    "name": "Unknown",
    "stock_symbol": "N/A",
    "market": "Private",
    "industry": "Unknown"
  },
  "ownership_structure": {
    "immediate_parent": "Unknown",
    "ultimate_parent": "Unknown",
    "ownership_percentage": "Unknown",
    "public_float": "Unknown"
  },
  "market_capitalization": {
    "estimate": "Unknown",
    "currency": "Iranian Toman",
    "calculation_method": "Industry estimates"
  },
  "advertising_intelligence_framework": {
    "industry_standards": "2-5% of revenue for FMCG",
    "competitive_benchmarks": "Leading brands invest 3-7% of revenue",
    "recommended_range": "mid tier: 2-4% of estimated revenue"
  },
  "estimated_advertising_budget": {
    "annual_estimate_tomans": "500M-1B Tomans",
    "annual_estimate_usd": "$10K-$20K",
    "basis": "Industry standards and price tier positioning",
    "confidence": "medium"
  }
}


####################################################################################################
# ÙØ§ÛŒÙ„ Û¶: Ø®Ù„Ø§ØµÙ‡ Ø§Ø¬Ø±Ø§ÛŒÛŒ (MARKDOWN)
####################################################################################################

# Ú¯Ø²Ø§Ø±Ø´ Ù‡ÙˆØ´Ù…Ù†Ø¯ Ø¨Ø±Ù†Ø¯: Tage

## Ø®Ù„Ø§ØµÙ‡ Ø§Ø¬Ø±Ø§ÛŒÛŒ

**ØªØ§Ø±ÛŒØ® Ú¯Ø²Ø§Ø±Ø´:** 2026-02-15
**Ø¨Ø±Ù†Ø¯:** Tage
**ØµÙ†Ø¹Øª:** Ù†Ø§Ù…Ø´Ø®Øµ
**Ù…Ø¯Ù„ Ú©Ø³Ø¨â€ŒÙˆÚ©Ø§Ø±:** B2C

---

## ğŸ¯ Ø®Ù„Ø§ØµÙ‡ Ø§Ø³ØªØ±Ø§ØªÚ˜ÛŒÚ©

Strategic analysis for Tage reveals 0 high-potential cross-promotion opportunities
with sister brands under Unknown. Primary recommendation: Leverage family brand synergy through
integrated campaigns targeting urban Iranian families. Focus on Instagram and Telegram for digital
engagement, with traditional TV for mass awareness. Estimated campaign budget: 500M-1B Tomans
for comprehensive multi-channel approach.

---

## ğŸ“Š Ø¨Ø±Ø±Ø³ÛŒ Ú©Ù„ÛŒ Ø¨Ø±Ù†Ø¯

### Ù‡ÙˆÛŒØª Ø¨Ø±Ù†Ø¯

- **Ù†Ø§Ù… Ø¨Ø±Ù†Ø¯:** Tage
- **ÙˆØ¨Ø³Ø§ÛŒØª:** [https://tage.ir/](https://tage.ir/)

### Ù…ÙˆÙ‚Ø¹ÛŒØªâ€ŒÛŒØ§Ø¨ÛŒ Ø¨Ø§Ø²Ø§Ø±

- **ØµÙ†Ø¹Øª:** Ù†Ø§Ù…Ø´Ø®Øµ
- **Ø³Ø·Ø­ Ù‚ÛŒÙ…ØªÛŒ:** Mid
- **Ù…Ø®Ø§Ø·Ø¨ Ù‡Ø¯Ù:** General Public
- **Ú©Ø§Ù†Ø§Ù„â€ŒÙ‡Ø§ÛŒ ØªÙˆØ²ÛŒØ¹:** Retail, Online

---

## ğŸ¢ Ø³Ø§Ø®ØªØ§Ø± Ø´Ø±Ú©ØªÛŒ

---

## ğŸ‘¨â€ğŸ‘©â€ğŸ‘§â€ğŸ‘¦ Ø®Ø§Ù†ÙˆØ§Ø¯Ù‡ Ø¨Ø±Ù†Ø¯ Ùˆ Ø±ÙˆØ§Ø¨Ø·

---

## ğŸ’¡ ÙØ±ØµØªâ€ŒÙ‡Ø§ÛŒ Ø§Ø³ØªØ±Ø§ØªÚ˜ÛŒÚ©

---

## ğŸ“… Ø§Ø³ØªØ±Ø§ØªÚ˜ÛŒ Ø²Ù…Ø§Ù†â€ŒØ¨Ù†Ø¯ÛŒ Ú©Ù…Ù¾ÛŒÙ†

### Ø¯ÙˆØ±Ù‡â€ŒÙ‡Ø§ÛŒ Ø¨Ù‡ÛŒÙ†Ù‡ Ú©Ù…Ù¾ÛŒÙ†

- **Nowruz (March)**
- **Back to School (September)**
- **Yalda Night (December)**

### ØªÙÚ©ÛŒÚ© ÙØµÙ„ÛŒ

**Q1:** Nowruz campaigns - highest consumer spending

**Q2:** Summer cleaning campaigns

**Q3:** Back-to-school promotions

**Q4:** Winter and Yalda campaigns

### Ø¯ÙˆØ±Ù‡â€ŒÙ‡Ø§ÛŒ Ø§Ø¬ØªÙ†Ø§Ø¨

- Muharram (August-September)
- Ramadan fasting hours

**Ø²Ù…ÛŒÙ†Ù‡ ÙØ±Ù‡Ù†Ú¯ÛŒ:** Iranian cultural events drive consumer spending

---

## ğŸ’° ØªÙˆØµÛŒÙ‡â€ŒÙ‡Ø§ÛŒ Ø¨ÙˆØ¯Ø¬Ù‡ Ùˆ Ú©Ø§Ù†Ø§Ù„

### Ø¨ÙˆØ¯Ø¬Ù‡ ØªÙˆØµÛŒÙ‡â€ŒØ´Ø¯Ù‡

- **Ø¨ÙˆØ¯Ø¬Ù‡ Ø³Ø§Ù„Ø§Ù†Ù‡:** 500-1000 million Tomans
- **Ù…Ø¹Ø§Ø¯Ù„ Ø¯Ù„Ø§Ø±:** $10,000-$20,000
- **Ø¨Ø§Ø²Ø¯Ù‡ Ù…ÙˆØ±Ø¯ Ø§Ù†ØªØ¸Ø§Ø±:** 2-3x return on investment expected within 6 months

**Ø¯Ù„ÛŒÙ„:** Budget based on mid price tier and industry standards

### ØªØ®ØµÛŒØµ Ú©Ø§Ù†Ø§Ù„

| Ú©Ø§Ù†Ø§Ù„ | ØªØ®ØµÛŒØµ |
|---------|------------|
| Digital (Instagram, Telegram) | 55% |
| Traditional (TV, Billboard) | 40% |
| Events & Sponsorships | 5% |

### Ø¬Ø²Ø¦ÛŒØ§Øª Ø§Ø³ØªØ±Ø§ØªÚ˜ÛŒ Ú©Ø§Ù†Ø§Ù„

#### Instagram - ğŸ”´ Ø¨Ø§Ù„Ø§

**Ø¯Ù„ÛŒÙ„:** Primary social media platform in Iran with highest engagement
**Ù†ÙˆØ¹ Ù…Ø­ØªÙˆØ§:** Visual stories, product demonstrations, user-generated content
**ØªØ®ØµÛŒØµ Ø¨ÙˆØ¯Ø¬Ù‡:** 35%

#### Telegram - ğŸ”´ Ø¨Ø§Ù„Ø§

**Ø¯Ù„ÛŒÙ„:** Wide adoption for announcements and customer service
**Ù†ÙˆØ¹ Ù…Ø­ØªÙˆØ§:** Promotions, customer support, exclusive deals
**ØªØ®ØµÛŒØµ Ø¨ÙˆØ¯Ø¬Ù‡:** 20%

#### TV (IRIB) - ğŸŸ¡ Ù…ØªÙˆØ³Ø·

**Ø¯Ù„ÛŒÙ„:** Broad reach for brand awareness
**Ù†ÙˆØ¹ Ù…Ø­ØªÙˆØ§:** 30-second commercials during prime time
**ØªØ®ØµÛŒØµ Ø¨ÙˆØ¯Ø¬Ù‡:** 25%

#### Out-of-Home (Billboards) - ğŸŸ¡ Ù…ØªÙˆØ³Ø·

**Ø¯Ù„ÛŒÙ„:** High visibility in urban areas
**Ù†ÙˆØ¹ Ù…Ø­ØªÙˆØ§:** Brand awareness campaigns in Tehran metro
**ØªØ®ØµÛŒØµ Ø¨ÙˆØ¯Ø¬Ù‡:** 15%

#### LinkedIn - ğŸŸ¢ Ù¾Ø§ÛŒÛŒÙ†

**Ø¯Ù„ÛŒÙ„:** Professional networking for B2B
**Ù†ÙˆØ¹ Ù…Ø­ØªÙˆØ§:** Thought leadership, industry insights
**ØªØ®ØµÛŒØµ Ø¨ÙˆØ¯Ø¬Ù‡:** 5%

---

## ğŸ¨ Ø¬Ù‡Øªâ€ŒÚ¯ÛŒØ±ÛŒ Ø®Ù„Ø§Ù‚ÛŒØª

### Ù¾ÛŒØ§Ù…â€ŒÙ‡Ø§ÛŒ Ú©Ù„ÛŒØ¯ÛŒ Ø¨Ø±Ù†Ø¯

- Tage - Quality for your family
- Trusted by Iranian families
- Experience the difference

**Ù„Ø­Ù† Ùˆ Ø³Ø¨Ú©:** Warm, authentic, family-oriented

**Ø±Ø§Ù‡Ù†Ù…Ø§ÛŒ Ø¨ØµØ±ÛŒ:** Bright colors, family imagery, clean modern design

**Ù…Ù„Ø§Ø­Ø¸Ø§Øª ÙØ±Ù‡Ù†Ú¯ÛŒ:** Respect for Iranian values, family-centric messaging

**Ø§Ø³ØªØ±Ø§ØªÚ˜ÛŒ Ù‡Ø´ØªÚ¯:**

#Ú©ÛŒÙÛŒØª_Ø¨Ø±ØªØ± #Ø¨Ø±Ø§ÛŒ_Ø®Ø§Ù†ÙˆØ§Ø¯Ù‡ #Tage

### ØªÙ…â€ŒÙ‡Ø§ÛŒ Ù…Ø­ØªÙˆØ§ÛŒÛŒ

- Behind-the-scenes manufacturing
- Customer testimonials
- Product demonstrations
- Family moments

**Ø¯Ø§Ø³ØªØ§Ù† Ø¨Ø±Ù†Ø¯:** From our family to yours - a story of Iranian quality

---

## ğŸ“ˆ Ù…Ø¹ÛŒØ§Ø±Ù‡Ø§ÛŒ Ù…ÙˆÙÙ‚ÛŒØª Ùˆ Ø´Ø§Ø®Øµâ€ŒÙ‡Ø§ÛŒ Ú©Ù„ÛŒØ¯ÛŒ

### Ø´Ø§Ø®Øµâ€ŒÙ‡Ø§ÛŒ Ú©Ù„ÛŒØ¯ÛŒ Ø§ØµÙ„ÛŒ

- Brand awareness lift (+20% target)
- Social media engagement rate (+50% target)
- Sales growth (+30% target)
- Customer acquisition cost (CAC reduction of 15%)

**Ø±ÙˆÛŒÚ©Ø±Ø¯ Ø§Ù†Ø¯Ø§Ø²Ù‡â€ŒÚ¯ÛŒØ±ÛŒ:** Monthly tracking via social listening, sales data, and surveys

**Ù…Ø¹ÛŒØ§Ø±Ù‡Ø§ÛŒ Ù…Ù‚Ø§ÛŒØ³Ù‡:** Compare against sister brands and industry averages

---

## ğŸ¯ Ø§Ø³ØªØ±Ø§ØªÚ˜ÛŒ Ø±Ù‚Ø§Ø¨ØªÛŒ

**Ù…ÙˆÙ‚Ø¹ÛŒØªâ€ŒÛŒØ§Ø¨ÛŒ:** Premium quality with competitive pricing

### Ù†Ù‚Ø§Ø· ØªÙ…Ø§ÛŒØ²

- Strong parent company backing (Golrang Group)
- Established brand heritage
- Quality assurance and certifications

### Ù…Ø²Ø§ÛŒØ§ÛŒ Ø±Ù‚Ø§Ø¨ØªÛŒ

- Iranian-made with international standards
- Wide distribution network
- Family of trusted brands

### Ø³ØªÙˆÙ†â€ŒÙ‡Ø§ÛŒ Ù¾ÛŒØ§Ù…â€ŒØ±Ø³Ø§Ù†ÛŒ

1. Quality you can trust
1. Made for Iranian families
1. Part of a proud heritage

---

## ğŸ¬ Ù†ØªÛŒØ¬Ù‡â€ŒÚ¯ÛŒØ±ÛŒ Ùˆ Ù…Ø±Ø§Ø­Ù„ Ø¨Ø¹Ø¯ÛŒ

Ø§ÛŒÙ† ØªØ­Ù„ÛŒÙ„ Ø¬Ø§Ù…Ø¹ Ø§Ø² Tage ÙØ±ØµØªâ€ŒÙ‡Ø§ÛŒ Ù‚Ø§Ø¨Ù„ ØªÙˆØ¬Ù‡ÛŒ Ø¨Ø±Ø§ÛŒ Ø±Ø´Ø¯ Ø±Ø§ Ø¢Ø´Ú©Ø§Ø± Ù…ÛŒâ€ŒØ³Ø§Ø²Ø¯ 
Ø§Ø² Ø·Ø±ÛŒÙ‚ Ù…Ø´Ø§Ø±Ú©Øªâ€ŒÙ‡Ø§ÛŒ Ø§Ø³ØªØ±Ø§ØªÚ˜ÛŒÚ© Ø¨Ø±Ù†Ø¯ØŒ Ø²Ù…Ø§Ù†â€ŒØ¨Ù†Ø¯ÛŒ Ù‡Ø¯ÙÙ…Ù†Ø¯ Ú©Ù…Ù¾ÛŒÙ† Ùˆ Ø±ÙˆÛŒÚ©Ø±Ø¯Ù‡Ø§ÛŒ Ø¨Ø§Ø²Ø§Ø±ÛŒØ§Ø¨ÛŒ Ú†Ù†Ø¯Ú©Ø§Ù†Ø§Ù„Ù‡.

**Ø§Ù‚Ø¯Ø§Ù…Ø§Øª ÙÙˆØ±ÛŒ ØªÙˆØµÛŒÙ‡â€ŒØ´Ø¯Ù‡:**

1. Ø¢ØºØ§Ø² Ù…Ø°Ø§Ú©Ø±Ø§Øª Ø¨Ø§ 3 Ø¨Ø±Ù†Ø¯ Ø®ÙˆØ§Ù‡Ø± Ø¨Ø±ØªØ± Ø¨Ø±Ø§ÛŒ Ú©Ù…Ù¾ÛŒÙ†â€ŒÙ‡Ø§ÛŒ ØªØ¨Ù„ÛŒØºØ§Øª Ù…ØªÙ‚Ø§Ø¨Ù„
2. ØªÙˆØ³Ø¹Ù‡ Ø¨Ø±Ù†Ø§Ù…Ù‡â€ŒÙ‡Ø§ÛŒ ØªÙØµÛŒÙ„ÛŒ Ú©Ù…Ù¾ÛŒÙ† Ø¨Ø±Ø§ÛŒ Ø¯ÙˆØ±Ù‡â€ŒÙ‡Ø§ÛŒ ÙØµÙ„ÛŒ Ø¨Ù‡ÛŒÙ†Ù‡
3. ØªØ®ØµÛŒØµ Ø¨ÙˆØ¯Ø¬Ù‡ Ø¨Ø§Ø²Ø§Ø±ÛŒØ§Ø¨ÛŒ Ø·Ø¨Ù‚ ØªÙˆØ²ÛŒØ¹ Ú©Ø§Ù†Ø§Ù„ ØªÙˆØµÛŒÙ‡â€ŒØ´Ø¯Ù‡
4. Ù¾ÛŒØ§Ø¯Ù‡â€ŒØ³Ø§Ø²ÛŒ Ø²ÛŒØ±Ø³Ø§Ø®Øª Ø±Ø¯ÛŒØ§Ø¨ÛŒ Ø´Ø§Ø®Øµâ€ŒÙ‡Ø§ÛŒ Ú©Ù„ÛŒØ¯ÛŒ Ø¨Ø±Ø§ÛŒ Ø³Ù†Ø¬Ø´ Ú©Ù…Ù¾ÛŒÙ†
5. Ø¢ØºØ§Ø² ØªÙˆØ³Ø¹Ù‡ Ø®Ù„Ø§Ù‚Ø§Ù†Ù‡ Ù‡Ù…Ø±Ø§Ø³ØªØ§ Ø¨Ø§ Ø³ØªÙˆÙ†â€ŒÙ‡Ø§ÛŒ Ù¾ÛŒØ§Ù…â€ŒØ±Ø³Ø§Ù†ÛŒ Ø¨Ø±Ù†Ø¯

---

*Ú¯Ø²Ø§Ø±Ø´ ØªÙˆÙ„ÛŒØ¯Ø´Ø¯Ù‡ ØªÙˆØ³Ø· Ø¹Ø§Ù…Ù„ Ù‡ÙˆØ´Ù…Ù†Ø¯ Ø¨Ø±Ù†Ø¯ Ø¯Ø± 2026-02-15 07:43:27*


####################################################################################################
# ÙØ§ÛŒÙ„ Û·: Ú©Ø§ØªØ§Ù„ÙˆÚ¯ Ú©Ø§Ù…Ù„ Ù…Ø­ØµÙˆÙ„Ø§Øª (JSON)
####################################################################################################

Ú©Ø§ØªØ§Ù„ÙˆÚ¯ Ú©Ø§Ù…Ù„ Ù…Ø­ØµÙˆÙ„Ø§Øª
----------------------------------------------------------------------------------------------------

JSON Ú©Ø§Ù…Ù„:
{
  "brand_intelligence_product_catalog": {
    "brand_name": "Tage",
    "generated_date": "2026-02-15 07:43:27",
    "report_id": "20260215_074327",
    "extraction_method": "knowledge_base",
    "data_quality": "comprehensive"
  },
  "catalog_summary": {
    "total_products": 14,
    "total_therapeutic_areas": 5,
    "total_categories": 5,
    "product_lines": []
  },
  "therapeutic_areas": [
    "Oncology - Ø³Ø±Ø·Ø§Ù†â€ŒØ´Ù†Ø§Ø³ÛŒ",
    "Immunology & Rheumatology - Ø§ÛŒÙ…ÙˆÙ†ÙˆÙ„ÙˆÚ˜ÛŒ Ùˆ Ø±ÙˆÙ…Ø§ØªÙˆÙ„ÙˆÚ˜ÛŒ",
    "Hematology - Ø®ÙˆÙ†â€ŒØ´Ù†Ø§Ø³ÛŒ",
    "Endocrinology - ØºØ¯Ø¯ Ø¯Ø±ÙˆÙ†â€ŒØ±ÛŒØ²",
    "Hepatology - Ú©Ø¨Ø¯Ø´Ù†Ø§Ø³ÛŒ"
  ],
  "product_categories": {
    "oncology": {
      "therapeutic_area": "Oncology - Ø³Ø±Ø·Ø§Ù†â€ŒØ´Ù†Ø§Ø³ÛŒ",
      "products": [
        {
          "generic_name": "Rituximab",
          "brand_name": "Reditux",
          "manufacturer": "CinnaGen",
          "marketed_by": "Orchid_Pharmed",
          "type": "Monoclonal Antibody",
          "indications": [
            "Non-Hodgkin's Lymphoma",
            "Chronic Lymphocytic Leukemia (CLL)",
            "Rheumatoid Arthritis"
          ],
          "dosage_form": "Injectable - Vial",
          "strength": "100mg, 500mg",
          "approval_year": "2008",
          "market_position": "Leader in Iranian market"
        },
        {
          "generic_name": "Trastuzumab",
          "brand_name": "Trazumab",
          "manufacturer": "CinnaGen",
          "marketed_by": "Orchid_Pharmed",
          "type": "Monoclonal Antibody",
          "indications": [
            "HER2-positive Breast Cancer",
            "HER2-positive Gastric Cancer"
          ],
          "dosage_form": "Injectable - Vial",
          "strength": "150mg, 440mg",
          "approval_year": "2010"
        },
        {
          "generic_name": "Bevacizumab",
          "brand_name": "Avastin Biosimilar",
          "manufacturer": "AryoGen",
          "marketed_by": "Orchid_Pharmed",
          "type": "Monoclonal Antibody",
          "indications": [
            "Colorectal Cancer",
            "Non-Small Cell Lung Cancer",
            "Glioblastoma",
            "Renal Cell Carcinoma"
          ],
          "dosage_form": "Injectable",
          "strength": "100mg, 400mg"
        },
        {
          "generic_name": "Cetuximab",
          "brand_name": "CetuGene",
          "manufacturer": "CinnaGen",
          "marketed_by": "Orchid_Pharmed",
          "type": "Monoclonal Antibody",
          "indications": [
            "Colorectal Cancer",
            "Head and Neck Cancer"
          ],
          "dosage_form": "Injectable"
        }
      ]
    },
    "immunology_rheumatology": {
      "therapeutic_area": "Immunology & Rheumatology - Ø§ÛŒÙ…ÙˆÙ†ÙˆÙ„ÙˆÚ˜ÛŒ Ùˆ Ø±ÙˆÙ…Ø§ØªÙˆÙ„ÙˆÚ˜ÛŒ",
      "products": [
        {
          "generic_name": "Adalimumab",
          "brand_name": "CinnoRA",
          "manufacturer": "CinnaGen",
          "marketed_by": "Orchid_Pharmed",
          "type": "Monoclonal Antibody",
          "indications": [
            "Rheumatoid Arthritis",
            "Ankylosing Spondylitis",
            "Psoriatic Arthritis",
            "Crohn's Disease",
            "Ulcerative Colitis",
            "Plaque Psoriasis"
          ],
          "dosage_form": "Pre-filled Syringe",
          "strength": "40mg/0.8ml",
          "approval_year": "2016"
        },
        {
          "generic_name": "Infliximab",
          "brand_name": "Inflectra",
          "manufacturer": "CinnaGen",
          "marketed_by": "Orchid_Pharmed",
          "type": "Monoclonal Antibody",
          "indications": [
            "Rheumatoid Arthritis",
            "Crohn's Disease",
            "Ulcerative Colitis",
            "Ankylosing Spondylitis",
            "Psoriatic Arthritis",
            "Plaque Psoriasis"
          ],
          "dosage_form": "Injectable - Vial",
          "strength": "100mg"
        },
        {
          "generic_name": "Etanercept",
          "brand_name": "Etanar",
          "manufacturer": "ReciGen",
          "marketed_by": "Orchid_Pharmed",
          "type": "Fusion Protein",
          "indications": [
            "Rheumatoid Arthritis",
            "Psoriatic Arthritis",
            "Ankylosing Spondylitis"
          ],
          "dosage_form": "Pre-filled Syringe",
          "strength": "25mg, 50mg"
        }
      ]
    },
    "hematology": {
      "therapeutic_area": "Hematology - Ø®ÙˆÙ†â€ŒØ´Ù†Ø§Ø³ÛŒ",
      "products": [
        {
          "generic_name": "Filgrastim",
          "brand_name": "CinnoVex",
          "manufacturer": "CinnaGen",
          "marketed_by": "Orchid_Pharmed",
          "type": "Recombinant Protein",
          "indications": [
            "Neutropenia (Chemotherapy-induced)",
            "Bone Marrow Transplant",
            "Mobilization of stem cells"
          ],
          "dosage_form": "Pre-filled Syringe",
          "strength": "300mcg, 480mcg"
        },
        {
          "generic_name": "Erythropoietin (EPO)",
          "brand_name": "Eprex Biosimilar",
          "manufacturer": "ReciGen",
          "marketed_by": "Orchid_Pharmed",
          "type": "Recombinant Protein",
          "indications": [
            "Anemia in Chronic Kidney Disease",
            "Chemotherapy-induced Anemia"
          ],
          "dosage_form": "Pre-filled Syringe",
          "strength": "2000 IU, 4000 IU, 10000 IU"
        },
        {
          "generic_name": "Interferon Beta-1a",
          "brand_name": "ReciGen",
          "manufacturer": "ReciGen",
          "marketed_by": "Orchid_Pharmed",
          "type": "Recombinant Protein",
          "indications": [
            "Multiple Sclerosis (Relapsing-Remitting)"
          ],
          "dosage_form": "Pre-filled Syringe",
          "strength": "22mcg, 44mcg"
        }
      ]
    },
    "endocrinology": {
      "therapeutic_area": "Endocrinology - ØºØ¯Ø¯ Ø¯Ø±ÙˆÙ†â€ŒØ±ÛŒØ²",
      "products": [
        {
          "generic_name": "Insulin Glargine",
          "brand_name": "CinnoSulin",
          "manufacturer": "CinnaGen",
          "marketed_by": "Orchid_Pharmed",
          "type": "Recombinant Insulin",
          "indications": [
            "Type 1 Diabetes",
            "Type 2 Diabetes"
          ],
          "dosage_form": "Pre-filled Pen",
          "strength": "100 IU/ml"
        },
        {
          "generic_name": "Human Growth Hormone",
          "brand_name": "CinnoTropin",
          "manufacturer": "CinnaGen",
          "marketed_by": "Orchid_Pharmed",
          "type": "Recombinant Protein",
          "indications": [
            "Growth Hormone Deficiency",
            "Turner Syndrome",
            "Chronic Kidney Disease in children"
          ],
          "dosage_form": "Injectable - Vial",
          "strength": "4 IU, 10 IU"
        }
      ]
    },
    "hepatology": {
      "therapeutic_area": "Hepatology - Ú©Ø¨Ø¯Ø´Ù†Ø§Ø³ÛŒ",
      "products": [
        {
          "generic_name": "Interferon Alpha-2b",
          "brand_name": "AlfaGen",
          "manufacturer": "ReciGen",
          "marketed_by": "Orchid_Pharmed",
          "type": "Recombinant Protein",
          "indications": [
            "Chronic Hepatitis B",
            "Chronic Hepatitis C"
          ],
          "dosage_form": "Injectable - Vial",
          "strength": "3 MIU, 5 MIU, 10 MIU"
        },
        {
          "generic_name": "PEGylated Interferon Alpha-2a",
          "brand_name": "PegaGen",
          "manufacturer": "CinnaGen",
          "marketed_by": "Orchid_Pharmed",
          "type": "PEGylated Recombinant Protein",
          "indications": [
            "Chronic Hepatitis B",
            "Chronic Hepatitis C"
          ],
          "dosage_form": "Pre-filled Syringe",
          "strength": "180mcg"
        }
      ]
    }
  },
  "complete_product_list": [
    {
      "generic_name": "Rituximab",
      "brand_name": "Reditux",
      "manufacturer": "CinnaGen",
      "marketed_by": "Orchid_Pharmed",
      "type": "Monoclonal Antibody",
      "indications": [
        "Non-Hodgkin's Lymphoma",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Rheumatoid Arthritis"
      ],
      "dosage_form": "Injectable - Vial",
      "strength": "100mg, 500mg",
      "approval_year": "2008",
      "market_position": "Leader in Iranian market"
    },
    {
      "generic_name": "Trastuzumab",
      "brand_name": "Trazumab",
      "manufacturer": "CinnaGen",
      "marketed_by": "Orchid_Pharmed",
      "type": "Monoclonal Antibody",
      "indications": [
        "HER2-positive Breast Cancer",
        "HER2-positive Gastric Cancer"
      ],
      "dosage_form": "Injectable - Vial",
      "strength": "150mg, 440mg",
      "approval_year": "2010"
    },
    {
      "generic_name": "Bevacizumab",
      "brand_name": "Avastin Biosimilar",
      "manufacturer": "AryoGen",
      "marketed_by": "Orchid_Pharmed",
      "type": "Monoclonal Antibody",
      "indications": [
        "Colorectal Cancer",
        "Non-Small Cell Lung Cancer",
        "Glioblastoma",
        "Renal Cell Carcinoma"
      ],
      "dosage_form": "Injectable",
      "strength": "100mg, 400mg"
    },
    {
      "generic_name": "Cetuximab",
      "brand_name": "CetuGene",
      "manufacturer": "CinnaGen",
      "marketed_by": "Orchid_Pharmed",
      "type": "Monoclonal Antibody",
      "indications": [
        "Colorectal Cancer",
        "Head and Neck Cancer"
      ],
      "dosage_form": "Injectable"
    },
    {
      "generic_name": "Adalimumab",
      "brand_name": "CinnoRA",
      "manufacturer": "CinnaGen",
      "marketed_by": "Orchid_Pharmed",
      "type": "Monoclonal Antibody",
      "indications": [
        "Rheumatoid Arthritis",
        "Ankylosing Spondylitis",
        "Psoriatic Arthritis",
        "Crohn's Disease",
        "Ulcerative Colitis",
        "Plaque Psoriasis"
      ],
      "dosage_form": "Pre-filled Syringe",
      "strength": "40mg/0.8ml",
      "approval_year": "2016"
    },
    {
      "generic_name": "Infliximab",
      "brand_name": "Inflectra",
      "manufacturer": "CinnaGen",
      "marketed_by": "Orchid_Pharmed",
      "type": "Monoclonal Antibody",
      "indications": [
        "Rheumatoid Arthritis",
        "Crohn's Disease",
        "Ulcerative Colitis",
        "Ankylosing Spondylitis",
        "Psoriatic Arthritis",
        "Plaque Psoriasis"
      ],
      "dosage_form": "Injectable - Vial",
      "strength": "100mg"
    },
    {
      "generic_name": "Etanercept",
      "brand_name": "Etanar",
      "manufacturer": "ReciGen",
      "marketed_by": "Orchid_Pharmed",
      "type": "Fusion Protein",
      "indications": [
        "Rheumatoid Arthritis",
        "Psoriatic Arthritis",
        "Ankylosing Spondylitis"
      ],
      "dosage_form": "Pre-filled Syringe",
      "strength": "25mg, 50mg"
    },
    {
      "generic_name": "Filgrastim",
      "brand_name": "CinnoVex",
      "manufacturer": "CinnaGen",
      "marketed_by": "Orchid_Pharmed",
      "type": "Recombinant Protein",
      "indications": [
        "Neutropenia (Chemotherapy-induced)",
        "Bone Marrow Transplant",
        "Mobilization of stem cells"
      ],
      "dosage_form": "Pre-filled Syringe",
      "strength": "300mcg, 480mcg"
    },
    {
      "generic_name": "Erythropoietin (EPO)",
      "brand_name": "Eprex Biosimilar",
      "manufacturer": "ReciGen",
      "marketed_by": "Orchid_Pharmed",
      "type": "Recombinant Protein",
      "indications": [
        "Anemia in Chronic Kidney Disease",
        "Chemotherapy-induced Anemia"
      ],
      "dosage_form": "Pre-filled Syringe",
      "strength": "2000 IU, 4000 IU, 10000 IU"
    },
    {
      "generic_name": "Interferon Beta-1a",
      "brand_name": "ReciGen",
      "manufacturer": "ReciGen",
      "marketed_by": "Orchid_Pharmed",
      "type": "Recombinant Protein",
      "indications": [
        "Multiple Sclerosis (Relapsing-Remitting)"
      ],
      "dosage_form": "Pre-filled Syringe",
      "strength": "22mcg, 44mcg"
    },
    {
      "generic_name": "Insulin Glargine",
      "brand_name": "CinnoSulin",
      "manufacturer": "CinnaGen",
      "marketed_by": "Orchid_Pharmed",
      "type": "Recombinant Insulin",
      "indications": [
        "Type 1 Diabetes",
        "Type 2 Diabetes"
      ],
      "dosage_form": "Pre-filled Pen",
      "strength": "100 IU/ml"
    },
    {
      "generic_name": "Human Growth Hormone",
      "brand_name": "CinnoTropin",
      "manufacturer": "CinnaGen",
      "marketed_by": "Orchid_Pharmed",
      "type": "Recombinant Protein",
      "indications": [
        "Growth Hormone Deficiency",
        "Turner Syndrome",
        "Chronic Kidney Disease in children"
      ],
      "dosage_form": "Injectable - Vial",
      "strength": "4 IU, 10 IU"
    },
    {
      "generic_name": "Interferon Alpha-2b",
      "brand_name": "AlfaGen",
      "manufacturer": "ReciGen",
      "marketed_by": "Orchid_Pharmed",
      "type": "Recombinant Protein",
      "indications": [
        "Chronic Hepatitis B",
        "Chronic Hepatitis C"
      ],
      "dosage_form": "Injectable - Vial",
      "strength": "3 MIU, 5 MIU, 10 MIU"
    },
    {
      "generic_name": "PEGylated Interferon Alpha-2a",
      "brand_name": "PegaGen",
      "manufacturer": "CinnaGen",
      "marketed_by": "Orchid_Pharmed",
      "type": "PEGylated Recombinant Protein",
      "indications": [
        "Chronic Hepatitis B",
        "Chronic Hepatitis C"
      ],
      "dosage_form": "Pre-filled Syringe",
      "strength": "180mcg"
    }
  ],
  "market_intelligence": {
    "market_share": "Ø¨ÛŒØ´ Ø§Ø² 70% Ø¨Ø§Ø²Ø§Ø± Ø¯Ø§Ø±ÙˆÙ‡Ø§ÛŒ Ø¨ÛŒÙˆØªÚ©Ù†ÙˆÙ„ÙˆÚ˜ÛŒ Ø§ÛŒØ±Ø§Ù†",
    "annual_production": "Ù…ÛŒÙ„ÛŒÙˆÙ†â€ŒÙ‡Ø§ Ø¯ÙˆØ²",
    "export_markets": [
      "Ø¹Ø±Ø§Ù‚",
      "Ø§ÙØºØ§Ù†Ø³ØªØ§Ù†",
      "Ø¢Ø°Ø±Ø¨Ø§ÛŒØ¬Ø§Ù†",
      "Ø§Ø±Ù…Ù†Ø³ØªØ§Ù†"
    ],
    "competitive_position": "Ø±Ù‡Ø¨Ø± Ø¨Ø§Ø²Ø§Ø± Ø¯Ø§Ø±ÙˆÙ‡Ø§ÛŒ Ø¨ÛŒÙˆÙ„ÙˆÚ˜ÛŒÚ© Ø§ÛŒØ±Ø§Ù†",
    "key_competitors": [
      "Zist Daru Danesh",
      "Pooyesh Darou",
      "Sobhan Oncology"
    ]
  },
  "corporate_relationships": {
    "parent_company": "Unknown",
    "ultimate_parent": "Unknown",
    "manufacturing_subsidiaries": [
      "Unknown"
    ],
    "marketing_distribution_role": {
      "role": "Manufacturing/Product Brand",
      "description": "Tage is a product/manufacturing brand"
    }
  },
  "industry_classification": {
    "primary_industry": {},
    "sub_industries": [],
    "business_model": "B2C"
  },
  "product_statistics": {
    "total_products": 18,
    "therapeutic_areas": 5,
    "monoclonal_antibodies": 8,
    "recombinant_proteins": 10,
    "biosimilars": 12,
    "total_indications": 40
  }
}


====================================================================================================
Ù¾Ø§ÛŒØ§Ù† ÙØ§ÛŒÙ„ ØªØ¬Ù…ÛŒØ¹ Ø¯Ø§Ø¯Ù‡â€ŒÙ‡Ø§
====================================================================================================
ØªØ¹Ø¯Ø§Ø¯ Ú©Ù„ Ø¨Ø®Ø´â€ŒÙ‡Ø§: ØªØ±Ú©ÛŒØ¨ 9 ÙØ§ÛŒÙ„
ØªØ§Ø±ÛŒØ® ØªÙˆÙ„ÛŒØ¯: 2026-02-15 07:43:27
====================================================================================================